Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)

May 7, 2026 updated by: Johns Hopkins Bloomberg School of Public Health
This study looks at how cannabis product label and marketing claims affect product perceptions, use expectancies, and use intentions among inexperienced and experienced cannabis users. Participants will answer online survey questions on their perceptions of a cannabis product advertisement.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study aims to specify how product label and marketing claims affect product perceptions, use expectancies, and use intentions among cannabis users. A randomized 4 (Sativa, Indica, Hybrid, no strain label) x 3 (energizing, sedative, no claim) online experiment will be conducted with a sample of adults from states that have legalized adult cannabis recreational use. Our main research questions are: (1) Do label and marketing claim affect (a) harm perceptions, (b) subjective effects expectancies (e.g., arousal, sedation), (c) willingness to use, and (d) willingness to use during daily activities (e.g., driving)? and (2) Do label and marketing claim interact to affect product perceptions, use expectancies, and use intentions?

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
2000

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • United States
    • Maryland
      • Baltimore, Maryland, United States, 21205
        • 2213 McElderry St.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age = 21+
  • Live in in a US state (or Washington D.C.) in which recreational cannabis sale is legal and implemented
  • For inexperienced users: lifetime cannabis use >1 & <= 10
  • For experienced users: lifetime cannabis use>10 & <100, past month cannabis use>0

Exclusion Criteria:

  • Under age 21
  • Does not live in a US state (or Washington D.C.) in which recreational cannabis sale is legal and implemented
  • Lifetime cannabis use >=100 times
  • Lifetime cannabis use <1 time
  • Lifetime cannabis use>10 & <100 AND past month cannabis use=0

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Indica/Energizing
Ad features Indica label + energizing claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Other: Claim
Presentation of claim on cannabis advertising material
Experimental: Indica/Sedating
Ad features Indica label + sedating claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Other: Claim
Presentation of claim on cannabis advertising material
Experimental: Indica/No claim
Ad features Indica label + no claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Experimental: Sativa/Energizing
Ad features Sativa label + energizing claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Other: Claim
Presentation of claim on cannabis advertising material
Experimental: Sativa/Sedating
Ad features Sativa label + sedating claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Other: Claim
Presentation of claim on cannabis advertising material
Experimental: Sativa/No claim
Ad features Sativa label + no claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Experimental: Hybrid/Energizing
Ad features Hybrid label + energizing claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Other: Claim
Presentation of claim on cannabis advertising material
Experimental: Hybrid/Sedating
Ad features Hybrid label + sedating claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Other: Claim
Presentation of claim on cannabis advertising material
Experimental: Hybrid/No claim
Ad features Hybrid label + no claim
Other: Strain label
Presentation of strain label on cannabis advertising material
Experimental: No strain/Energizing
Ad features no strain label + energizing claim
Other: Claim
Presentation of claim on cannabis advertising material
Experimental: No strain/Sedating
Ad features no strain label + sedating claim
Other: Claim
Presentation of claim on cannabis advertising material
No Intervention: No strain/No claim
Ad features no strain label + no claim

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Harm perception - One time use
Time Frame: Immediately after viewing ad
How harmful participant perceives the product to be after one time use. Participants will answer a survey item, In your opinion, what is the level of risk to one's health from using the product you just viewed one time?; with response options ranging from 0-Very low risk to 4-Very high risk.
Immediately after viewing ad
Harm perception - Daily use
Time Frame: Immediately after viewing ad
How harmful participant perceives the product to be with daily use. Participants will answer a survey item, In your opinion, what is the level of health risk from using the product you just viewed on a daily basis?; with response options ranging from 0-Very low risk to 4-Very high risk.
Immediately after viewing ad
Expectancy effects
Time Frame: Immediately after viewing ad
Effects participant expects to feel after using the product. Participants will answer a survey item, Please rate the extent to which you expect to feel each of the following effects [paranoid; panicked; fearful; anxious; suspicious; like my heart is racing; sluggish; drowsy; out of it; slow; lazy; excited; heightened senses; sociable; creative; wise; in tune with nature; focused; productive; sleepy; happy; euphoric; calm; relaxed; pain-free] after using the product you just viewed; with response options ranging from 0-not at all to 10-extremely.
Immediately after viewing ad
Willingness to use
Time Frame: Immediately after viewing ad
How willing participant is to use the product. Participants will answer a survey item, How willing would you be to use the product you just viewed?; with response options ranging from 0-Not at all willing to 4-Very willing.
Immediately after viewing ad
Willingness to use during daily activities
Time Frame: Immediately after viewing ad
How willing participant is to use the product during daily activities. Participants will answer a survey item, How willing would you be to use the product you just viewed if you [wanted to concentrate; wanted to relax; wanted to socialize; wanted to do a creative activity (e.g., art, music); wanted to feel happier; wanted to relieve medical symptoms/treat a medical condition/mental health condition; were going to drive a car in the next 30 minutes; were going to bed in the next 30 minutes; were planning to stay home for the next several hours; were going to work in the next 30 minutes; were at a party]?; with response options ranging from 0-Not at all willing to 4-Very willing.
Immediately after viewing ad

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Johns Hopkins Bloomberg School of Public Health

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute on Drug Abuse (NIDA)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Meghan Moran, PhD, Johns Hopkins University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 1, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 7, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 7, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRB00034819
  • 5R01DA059584 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified participant responses will be shared as needed to comply with grant and publication policies.

IPD Sharing Time Frame

IPD and supporting information will be available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the funding period.

IPD Sharing Access Criteria

Data from all aims will be deposited in the Johns Hopkins Research Data Repository. This archive provides open access to be downloaded freely by users. The Johns Hopkins Research Data Repository is a searchable archive in which JHU researchers may upload datasets and associated documentation. A persistent identifier (DOI) is provided. Metadata, including searchable keywords, are provided. Data are findable to the public.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cannabis Use

Clinical Trials on Strain label

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings